Table 1.

Characteristics of the patients with precocious puberty developing adverse reaction

Patient number	Age at the beginning of the treatment (years)	Gender	Additional Chronic Disease	GnRHa depot	Dose of GnRHa	Number of the injection at the time of reaction and interval between the reaction	Symptoms	Continuation of the treatment	Reactıon type	Who causality assesment scale
1	8.5	F	-	TA	3.75 mg/month	20th and 21st Immediately after	Tremor at both hands	Discontinued	Adverse reaction	Probable/likely
2	9	F	-	TA	3.75 mg/month	11th Immediately after	Vomiting	Discontinued	Hypersensitivity reaction	Possible
3	7.5	F	-	TA	3.75 mg/month	1st 72 hour after	Urticarial rash	Discontinued	Hypersensitivity reaction	Probable/likely
4	8	M	Bipolar disease, Autism spectrum disorder, hypothyroidism	LA	3.75 mg/month	9th 1 week later	Sterile abscess	Switched to TA treatment	Hypersensitivity reaction	Probable/likely
5	8 years 9 month	F	-	LA	3.75 mg/month	4th 10 days later	Sterile abscess	Switched to TA treatment	Hypersensitivity reaction	Probable/likely
6	7 years 11 month	F	-	LA	3.75 mg/month	3rd 1 week later	Sterile abscess	Switched to 11.25 mg per 3 month	Hypersensitivity reaction	Probable/likely
7	10 years 1 month	M	-	TA	3.75 mg/month	5th Immediately after	Musculoskeletal stiffness	Discontinued	Adverse reaction	Probable/likely